Translating mRNA
Educational Webinar Series
The Pfizer Vaccines US Medical Affairs Team invites you to attend an educational webinar series titled Translating mRNA which is focused on providing education on COVID-19 and vaccination. The webinar series is designed to communicate scientific information which may include recent study results to inform healthcare providers regarding Pfizer and BioNTech's COVID-19 vaccines.
The webinar series will include a live question-and-answer session with Pfizer medical experts.
We are hosting a Translating mRNA session on the topic below
Older Adults Continue to Bear a Disproportionate Burden of COVID-19
Date and Time:
Thursday, 22 August 2024: 12:00 pm – 12:30 pm ET
Speaker: Santiago Lopez, MD
US Senior Medical Director mRNA Team Lead, Pfizer mRNA Vaccines, Medical and Scientific Affairs
Intended Audience: US healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants.
Continuing medical education credit is NOT associated with this event.
Emergency use Authorization
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 6 months through 11 years of age. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
For US Full Prescribing Information and EUA Fact Sheet for Healthcare Providers, please visit www.cvdvaccine-us.com